Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2024-12-16 DOI:10.1002/hon.70010

A. Zduniak, E. Lévêque, S. Draye-Carbonnier, S. Becker, D. Tonnelet, S. Dubois, P. Vera, H. Tilly, F. Jardin, P. Decazes, V. Camus

{"title":"Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients","authors":"A. Zduniak, E. Lévêque, S. Draye-Carbonnier, S. Becker, D. Tonnelet, S. Dubois, P. Vera, H. Tilly, F. Jardin, P. Decazes, V. Camus","doi":"10.1002/hon.70010","DOIUrl":null,"url":null,"abstract":"We aimed to explore the predictive value of total metabolic tumor volume (TMTV) and beta-2-microglobulin (B2M) levels in patients with follicular lymphoma (FL) with a high tumor burden receiving standard first-line immunochemotherapy. We analyzed 125 patients with the following characteristics: median age, 61 years (55; 67), advanced-stage disease, 88.8%; high FLIPI, 49.6%; TMTV, > 510 cm3; B2M, > 3 mg/L (24.8%); and R-CHOP-like treatment, 86.4%. We defined the following categories: low-risk (36%), TMTV ≤ 510 cm3 and B2M ≤ 3 mg/L; intermediate-risk (45.6%), TMTV > 510 cm3 or B2M > 3 mg/L; and high-risk (18.4%), TMTV > 510 cm3 and B2M > 3 mg/L. The 5-year overall survival rates were estimated to be 96.1%, 89.1% and 73.7% for low-, intermediate- and high-risk patients, respectively (p = 0.003). Patients at intermediate and high risk according to the TMTV/B2M score were at high risk of disease progression within 24 months of treatment initiation (HR = 2.45 [95% CI: 1.23–4.85] and HR = 3.75 [95% CI: 1.7–8.2], respectively). This TMTV/B2M score may identify patients with the highest unmet medical needs.","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70010","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We aimed to explore the predictive value of total metabolic tumor volume (TMTV) and beta-2-microglobulin (B2M) levels in patients with follicular lymphoma (FL) with a high tumor burden receiving standard first-line immunochemotherapy. We analyzed 125 patients with the following characteristics: median age, 61 years (55; 67), advanced-stage disease, 88.8%; high FLIPI, 49.6%; TMTV, > 510 cm³; B2M, > 3 mg/L (24.8%); and R-CHOP-like treatment, 86.4%. We defined the following categories: low-risk (36%), TMTV ≤ 510 cm³ and B2M ≤ 3 mg/L; intermediate-risk (45.6%), TMTV > 510 cm³ or B2M > 3 mg/L; and high-risk (18.4%), TMTV > 510 cm³ and B2M > 3 mg/L. The 5-year overall survival rates were estimated to be 96.1%, 89.1% and 73.7% for low-, intermediate- and high-risk patients, respectively (p = 0.003). Patients at intermediate and high risk according to the TMTV/B2M score were at high risk of disease progression within 24 months of treatment initiation (HR = 2.45 [95% CI: 1.23–4.85] and HR = 3.75 [95% CI: 1.7–8.2], respectively). This TMTV/B2M score may identify patients with the highest unmet medical needs.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.